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Abstract
Background
Rapid identification of the etiological agent in bloodstream infections is of vital importance
for the early administration of the most appropriate antibiotic therapy. Molecular methods
may offer an advantage to current culture-based microbiological diagnosis. The goal of this
study was to evaluate the performance of IRIDICA, a platform based on universal genetic
amplification followed by mass spectrometry (PCR/ESI-MS) for the molecular diagnosis of
sepsis-related pathogens directly from the patient’s blood.
Methods
A total of 410 whole blood specimens from patients admitted to Emergency Room (ER) and
Intensive Care Unit (ICU) with clinical suspicion of sepsis were tested with the IRIDICA BAC
BSI Assay (broad identification of bacteria and Candida spp.). Microorganisms grown in cul-
ture and detected by IRIDICA were compared considering blood culture as gold standard.
When discrepancies were found, clinical records and results from other cultures were taken
into consideration (clinical infection criterion).
Results
The overall positive and negative agreement of IRIDICA with blood culture in the analysis
by specimen was 74.8% and 78.6%, respectively, rising to 76.9% and 87.2% respectively,
when compared with the clinical infection criterion. Interestingly, IRIDICA detected 41 clini-
cally significant microorganisms missed by culture, most of them from patients under antimi-
crobial treatment. Of special interest were the detections of oneMycoplasma hominis and
twoMycobacterium simiae in immunocompromised patients. When ICU patients were
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analyzed separately, sensitivity, specificity, positive and negative predictive values com-
pared with blood culture were 83.3%, 78.6%, 33.9% and 97.3% respectively, and 90.5%,
87.2%, 64.4% and 97.3% respectively, in comparison with the clinical infection criterion.
Conclusions
IRIDICA is a promising technology that offers an early and reliable identification of a wide
variety of pathogens directly from the patient’s blood within 6h, which brings the opportunity
to improve management of septic patients, especially for those critically ill admitted to the
ICU.
Introduction
Bloodstream infection is a life-threatening illness due to the presence of microorganisms or
their toxins in the blood [1]. The systemic deleterious host response to this infection can lead
to severe sepsis and septic shock, which affect millions of people around the world with an
increasing incidence [2]. Once the symptoms are recognized, the administration of antibiotic
therapy during the first hour is strongly recommended [2], as every hour gained in initiating
proper antimicrobial therapy significantly increases the probability of patient survival [3].
However, the current gold standard still relies on culture, which may take up to 3 days before
obtaining the identification and performing the antimicrobial susceptibility testing. Thus,
rapid identification of the causal agent directly from the patient’s blood would be desirable, as
it would allow clinicians to readdress the initial antibiotic therapy if necessary, before culture-
based identification and susceptibility testing results are available.
A few years ago, an innovative technology based on universal PCR amplification coupled
with mass spectrometry was described (PCR/ESI-MS) [4,5]. The first version of this technol-
ogy, although promising, showed a moderate sensitivity ranging from 50% to 68% for the diag-
nosis of bloodstream infections (in comparison with blood culture results plus other
microbiological findings) [6,7]. A newer version of this technology called IRIDICA (Ibis Biosci-
ences, Carlsbad, CA) is in development. Its main improvement is an enhanced sensitivity, up
to 83–91%, due to an increase in the volume of blood tested (5 mL instead of 1.25 mL in the
former version), the optimization of PCR conditions and reagents to be tolerant of high loads
of human DNA, and an improved downstream processing and analysis step to ensure high sen-
sitivity [8]. The goal of this study was to analyze the clinical performance of this new platform
for the diagnosis of bloodstream infections as well as its ability for identifying a wide range of
pathogens.
Materials and Methods
Ethics statement
Written informed consent was obtained from all patients or their guardians. This study was
approved by the Clinical Research Ethics Committee at Germans Trias i Pujol University Hos-
pital (“Comité Ético de Investigación Clínica”, CEIC).
Patients and specimens
This was an observational prospective study including a total of 405 patients admitted to the
ICU or ER (median age 66 years, range 16–101; 246 male and 161 female) with a suspicion of
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sepsis according to the American College of Chest Physicians/Society of Critical Care Medicine
(ACCP/SCCM) criteria [9], and enrolled between September 2012 and March 2013 at a tertiary
care center in Spain (Fig 1). For each patient, one extra whole blood specimen was collected in
an EDTA tube under aseptic conditions at the same time as the inoculation of the blood culture
for routine microbiological testing (at the onset of fever or other clinical signs of sepsis). For
five patients, a blood specimen from two different sepsis episodes was included adding up to
410 specimens. The result of the paired blood culture for each specimen was recorded. Over
the study period, a blood specimen was obtained for 222 ICU patients (median age 57.7 years,
range 16–83; 138 male, 82 female), which were all tested by IRIDICA. These corresponded to
32 specimens with a paired positive blood culture and 190 with a paired negative blood culture.
In order to further assess the ability of the technology for identifying a wider range of patho-
gens, we also included 188 specimens with paired positive blood culture from ER patients
(median 71.5 years, range 20–101; 110 male, 80 female), as this clinical unit is the source of
60% of blood cultures sent to the Microbiology laboratory. Those patients in which skin con-
taminants were identified by blood culture were excluded from this study (n = 56 cases with 59
microorganisms isolated from a single positive culture bottle with coagulase-negative staphylo-
cocci (n = 46), Streptococcus spp. (n = 5),Micrococcus spp. (n = 3), Corynebacterium spp.
(n = 2), Bacillus spp. (n = 1), Propionibacterium spp. (n = 1), and Stenotrophomonas maltophi-
lia (n = 1)). Whole blood specimens were stored at -20°C until testing at Ibis Biosciences.
Conventional microbiological methods
For each adult patient, a set of two blood cultures, including two aerobic and one anaerobic
blood culture bottles, were inoculated with up to 10 mL of blood each. The blood culture bot-
tles were incubated in the Bactec 9240 blood culture system (Becton Dickinson, Franklin
Lakes, NJ, USA) for up to 5 days. The identification and susceptibility testing of the microor-
ganisms were achieved using the Vitek-2 Compact system (BioMérieux, Marseille-L’Étoile,
France) directly from positive blood culture bottles after performing a Gram stain and a con-
centration procedure [10,11]. Conventional cultures were also performed, following standard
Fig 1. Flowchart depicting the study design.
doi:10.1371/journal.pone.0140865.g001
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microbiological methods for identification and antibiotic susceptibility testing (disc diffusion
and minimum inhibitory concentration methods) as required.
Specimen processing with IRIDICA
Specimen testing with IRIDICA (Ibis Biosciences) was performed according to the manufac-
turer’s instructions using the IRIDICA BAC BSI Assay (Ibis Biosciences-Abbott Molecular
(Des Plaines, IL). The work presented here was done using IRIDICA system under develop-
ment. IRIDICA (CE-IVD) is now commercially available (http://iridica.abbott.com/). As previ-
ously described [8], this process includes automated DNA extraction, PCR set-up, PCR
amplification, amplicon purification, and electrospray ionization time-of-flight mass spec-
trometry (PCR/ESI-MS), leading to microbial identification from whole blood in 6h. Computa-
tional matching of observed amplicon base compositions to a signature database provides
broad-spectrum microbial identification. Briefly, 5 mL whole blood samples were chemically
and mechanically lysed and an extraction control was added to each specimen for process
monitoring purposes. DNA extraction and PCR set-up was automatically performed by a sin-
gle instrument using pre-filled individual disposable sample preparation cartridges and pre-
filled 16-well PCR reaction strips. The BAC BSI Assay utilizes several conserved-site primer
pairs designed to amplify variable (and thereby discriminable) products from a broad range of
bacteria and Candida spp., as well as primer pairs targeted to common antibiotic resistance loci
conferring resistance to methicillin (mecA), vancomycin (vanA and vanB) and carbapenems
(KPC). PCR products were then desalted and concentrated relative to human genomic DNA in
an automated system and analyzed through ESI-MS. The base compositions of detected ampli-
con strands were deduced from the measured masses and compared with a reference database,
leading to the identification of the microorganisms present in clinical samples. Internal cali-
brants present in each reaction allowed for relative (qualitative) approximation of target con-
centrations (expressed as levels), which in turn were used to limit noise- and contamination-
derived background detections through thresholding of positive signals.
Data interpretation and statistical analysis
For each specimen, the results obtained with IRIDICA were compared with those obtained
using conventional methods (blood culture was considered the gold standard). When discrep-
ancies between these methods were found, the clinical significance of the discrepant results was
determined by comparison with a constructed “clinical infection criterion”; for this purpose, a
clinical microbiologist together with a clinician were asked to retrospectively evaluate the dis-
crepant results obtained by IRIDICA and to interpret them in the same way as the blood cul-
ture results are evaluated: the clinical records of the patients were reviewed in order to identify
the diagnosed focus of infection, as well as the results of cultures from other specimens (i.e.
microorganisms detected only by IRIDICA were considered true positives when the same
microorganism had been isolated from a culture from another specimen type reflecting the
focus of infection or supported by the nature of the underlying infection).
Since polymicrobial detections are not uncommon in bloodstream infections, the results
obtained by IRIDICA and blood culture were compared at two levels using the two aforemen-
tioned gold standards: 1) by microorganism: a direct comparison for each microorganism iso-
lated by conventional methods vs. the same microorganism detected by the molecular method,
taking into consideration all microorganisms identified; and 2) by specimen: for each specimen
with a single detection, matched positive or negative results by each method were recorded. In
the latter case, specimens with polymicrobial detections were excluded, as they could not be
properly classified (i.e. both methods agreed in some but not all microorganisms identified). In
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those terms, the Cohen’s Kappa coefficient of agreement by microorganism, and the positive
and negative agreement by microorganism and by specimen were calculated with OpenEpi
software [12]. In the ICU setting positive and negative agreements were equivalent to sensitiv-
ity and specificity, as all blood specimens consecutively obtained during the study period were
tested (including specimens with both positive and negative paired blood culture). The positive
and negative predictive values were also calculated both by microorganism and by specimen in
this subgroup of patients. IRIDICA performance was compared between ICU and ER sub-
groups using the Pearson's chi-squared test (χ2). Clinical and molecular quantitative variables
of interest were compared between groups using the Mann-Whitney U test (non-Normal dis-
tribution), and data was expressed as median and range. P-values<0.05 were considered sig-
nificant. Statistical analyses were performed using the statistical software package SPSS v15.0.
Results
Data analysis was performed on 408 specimens (220 from ICU and 188 from ER), as an invalid
IRIDICA result was obtained in two cases due to the lack of detection of the extraction control.
Overall agreement between both methods by microorganism
In comparison with blood culture, IRIDICA showed 73.3% positive concordance (detection of
the same microorganism by the two methods) and 64.1% negative concordance (negative by
the two methods) (Table 1). IRIDICA detected 80 microorganisms that did not grow in blood
culture; 41 (51.2%) of these were supported by clinical facts (S1 Table). On the contrary, the
presence of 7 (8.8%) microorganisms could not be supported by clinical evidence (S1 Table),
and another 32 (40%) microorganisms were considered clinically irrelevant contaminants
from the skin flora (i.e. coagulase-negative staphylococci, Propionibacterium acnes, etc.) or
from the environment (i.e.Methylobacterium spp., Pseudomonas putida, etc.) (S2 Table).
When the results were reanalyzed taking clinical information into consideration, the positive
and negative agreement were, respectively, 77.2% and 78.6% (Table 1). All microorganisms
with clinical significance were identified by IRIDICA at species level except for five (one Acine-
tobacter baumannii identified as Acinetobacter spp., one each Streptococcus pneumoniae and
Table 1. Agreement betweenmethods according to the two gold standards used by microorganisms isolated by conventional microbiological
methods and detected by IRIDICA.
Global Emergency Room Intensive Care Unit
BC gold
standard
Clinical infection
criterion
BC gold
standard
Clinical infection
criterion
BC gold standard Clinical infection
criterion
Matched positives (n) 176 217a 147 152a 29 65 a
Matched negatives (n) 143 143 n.a. n.a. 143 143
IRIDICA overcalls (n) 80 39 21 16 59 23
IRIDICA misses (n) 64 64 56 56 8 8
Overall agreement (%) 68.9 77.8 n.a. n.a. 72.0 87.0
Positive agreement (%) 73.3 77.2 72.4 73.1 78.4 b 89.0 b
Negative agreement (%) 64.1 78.6 n.a. n.a. 70.8 b 86.1 b
a IRIDICA overcalls with clinical signiﬁcance were classiﬁed as matched positives according the clinical infection criterion.
b Positive and negative agreement correspond to sensitivity and speciﬁcity, as all blood specimens consecutively obtained during the study period were
tested (including specimens with both positive and negative paired blood culture).
n.a., not applicable.
doi:10.1371/journal.pone.0140865.t001
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Streptococcus viridans group as Streptococcus spp., and two potential Aspergillus spp. as “Fun-
gus detected, no identification can be provided”). The microorganisms with clinical signifi-
cance isolated by culture or detected by IRIDICA are listed in Table 2.
Overall agreement between both methods by specimen
Polymicrobial infections with clinical significance were detected by either or both methods in
28 out of 245 specimens (11.4%) (S3 Table). Given that both methods agreed in some but not
Table 2. Microorganisms with clinical significance identified by either or both methods.
Blood culture and IRIDICA Blood culture only IRIDICA only
Gram-positive bacteria Staphylococcus aureus 8 3 3
Coagulase-negative staphylococci 4 4 0
Streptococcus pneumoniae 8 5 3
Viridans streptococci 4 3 0
Granulicatella spp. 1 0 0
β-hemolytic Streptococcus 3 2 2
Enterococcus spp. 15 6 1
Streptococcus gallolyticus 1 3 1
Listeria monocytogenes 1 2 0
Clostridium spp. 0 1 0
Bacillus spp. 0 1 0
Lactobacillus spp. 0 1 0
Mycobacterium simiae 0 0 2
Subtotal 45 31 12
Gram-negative bacteria Escherichia coli 85 18 7
Klebsiella pneumoniae/oxytoca 13 0 5
Enterobacter cloacae/aerogenes 10 3 3
Proteus mirabilis 4 2 0
Salmonella enterica sv. Enteritidis 1 0 0
Serratia marcescens 1 1 0
Pseudomonas aeruginosa 8 2 3
Pseudomonas spp. 3 0 0
Stenotrophomonas maltophilia 2 0 0
Acinetobacter baumannii 1 0 0
Elisabethkingia meningoseptica 1 0 0
Haemophilus inﬂuenzae 0 1 1
Mycoplasma hominis 0 0 1
Subtotal 129 27 20
Anaerobic bacteria 0 1 4
Fungi Candida albicans 0 1 2
Candida tropicalis 1 0 1
Candida parapsilosis 1 1 0
Candida glabrata 0 1 0
Candida lusitanie 0 1 0
Candida famata 0 1 0
Fungus detected, no ID provided 0 0 2
Subtotal 2 5 5
TOTAL 176 64 41
doi:10.1371/journal.pone.0140865.t002
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all the microorganisms identified, these apparent polymicrobial samples were excluded from
this analysis. Among the rest of specimens (n = 380), when blood culture was taken as the gold
standard the positive and negative agreement of IRIDICA were 74.8% and 78.6% respectively,
and those values rose to 76.9% and 87.2% when re-analyzed with the clinical infection criterion
(Table 3).
IRIDICA performance in ICU patients
In the analysis by microorganism, the overall agreement between methods was 72.0% (κ = 0.315)
and the sensitivity, specificity and positive and negative predictive values of IRIDICA in compar-
ison with blood culture were 78.4%, 70.8%, 33% and 95%, respectively (Table 1). When discrep-
ancies found were evaluated using the clinical infection criterion (S1 Table), the overall
agreement was 87% (κ = 0.711) and the values of analytical performance rose to 89%, 86.1%,
73.9% and 95%, respectively. Fourteen polymicrobial infections by either or both methods were
excluded in order to perform the analysis by specimen (S3 Table). In those terms, the sensitivity,
specificity and positive and negative predictive values in comparison with blood culture were
83.3%, 78.6%, 33.9% and 97.3% respectively, and rose to 90.5%, 87.2%, 64.4% and 97.3% respec-
tively when considering the clinical infection criterion (Table 3).
IRIDICA performance in ER patients
For this subgroup, we only included patients with a positive blood culture. According to the
blood culture positivity rate in our center (8.2–12.2%), about 1860 patients with a negative cul-
ture would have had to be included in order to reach the 188 positive blood cultures tested,
which was not feasible. From the 203 microorganisms isolated by culture, 147 were correctly
detected by IRIDICA. Thus, the positive agreement by microorganism in comparison with
blood culture was 72.4% (Table 1). A total of five microorganisms with clinical significance
were detected by IRIDICA only, giving a positive agreement of 73.1% when the clinical infec-
tion criterion was used. When analyzed by specimen, the positive agreement was 73.6% either
comparing with blood culture or clinical infection criterion (128 matched detections out of 174
monomicrobial infections) (Table 3).
Table 3. Agreement betweenmethods according to the two gold standards used on specimens with a unique isolation/detection.
Global Emergency Room Intensive Care Unit
BC gold
standard
Clinical infection
criterion
BC gold
standard
Clinical infection
criterion
BC gold standard Clinical infection
criterion
Matched positives (n) 148 166a 128 128 20 38 a
Matched negatives (n) 143 143 n.a. n.a. 143 143
IRIDICA overcalls (n) 39 21 0 0 39 21
IRIDICA misses (n) 50 50 46 46 4 4
Overall agreement (%) 76.6 81.3 n.a. n.a. 79.1 87.9
Positive agreement (%) 74.8 76.9 73.6 73.6 83.3b 90.5 b
Negative agreement (%) 78.6 87.2 n.a. n.a. 78.6 b 87.2 b
a IRIDICA overcalls with clinical signiﬁcance were classiﬁed as matched positives according the Clinical infection Criterion.
b Positive and negative agreement correspond to sensitivity and speciﬁcity, as all blood specimens consecutively obtained during the study period were
tested (including specimens with both positive and negative paired blood culture).
n.a., not applicable.
doi:10.1371/journal.pone.0140865.t003
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Assessment of factors potentially influencing performance of the
molecular method
In those sepsis cases with a positive blood culture, several variables regarding both the culture
(time to positivity) and the paired whole blood specimen (leukocyte count, storage time at
-20°C) were compared between IRIDICA-negative and -positive specimens in order to find out
if they were related to positivity by the molecular method. No statistically significant associa-
tions were found in the median white cell count between IRIDICA-negative and -positive speci-
mens (11.9×106 vs. 11.6×106 cells/mL). Whole blood specimens had been stored for variable
periods of time (range, 5–23 months; median, 13 months), but the median storage time was
comparable between the two groups of specimens (12 months in IRIDICA negative vs. 13
months in IRIDICA positive). The difference in the time to positivity of the blood culture was
marginally significant; specimens with an IRIDICA-positive result, tended to have a paired
blood culture that was called positive earlier (the time to positivity of the blood culture was
shorter: 14.5 vs. 15.5 h, p = 0.87). When comparing ICU vs. ER patients, the median of genomes
per well by IRIDICA was significantly higher (p = 0.011) in the ICU group (median, 97
genomes/well; range, 15–229) than in the ER group (median, 24.5 genomes/well; range, 3–370).
Detection of antibiotic resistance genes
The resistance markers detected by the molecular method in this study are depicted in Table 4.
The resistance markermecA was detected by IRIDICA in eight whole blood specimens, being
four of them concordant with the result obtained with the conventional methods. From the
other four detections, only one (Staphylococcus aureus,mecA) was supported by other microbi-
ological findings, as the patient also had a bronchial aspirate positive for methicillin-resistant S.
aureus. While none of the enterococci isolated and identified by conventional methods in this
study were resistant to vancomycin or teicoplanin, IRIDICA detected the resistance markers
vanA and vanB in two different specimens with an Enterococcus faecium.
Discussion
Sepsis is a severe syndrome where time is crucial to the optimal patient management. There is
a clear need to administer the appropriate antimicrobial therapy as soon as possible, as it will
have a positive impact on patient’s survival [2,3]. However, the identification of the etiological
agent from positive blood cultures may take 24–48h. Being able to detect and identify the
Table 4. Description of the antibiotic resistancemarkers detected in this study.
Antibiotic Identiﬁcation and AST by conventional methods Identiﬁcation and resistance markers by IRIDICA
Methicillin Coagulase-negative staphylococci, resistant Staphylococcus haemolyticus, Stahphylococcus epidermidis, mecA
S. epidermidis, resistant S. epidermidis, mecA
Staphylococcus aureus resistant S. aureus, mecA
Negative S. aureus, mecA (clinically signiﬁcant)
Negative S. epidermidis, mecA (contaminant)
Negative S. hominis, mecA (contaminant)
Negative S. aureus, mecA (no clinical explanation was found for this detection)
Vancomycin/ Teicoplanin Enterococcus faecium, susceptible E. faecium, vanA
E. faecium, susceptible E. faecium, vanB
Carbapenems - -
AST, antibiotic susceptibility testing.
doi:10.1371/journal.pone.0140865.t004
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causal pathogen directly from blood would speed the diagnosis and, therefore, improve the
management of septic patients. Although several molecular methods designed for this purpose
have been commercially available for several years, reported sensitivities are moderate in most
cases and are not consistent across studies [13–17]. Given that in bloodstream infections
microorganisms are present at low levels, working directly from small volumes of whole blood
is an inherent limitation of molecular methods [17,18]. In order to overcome this issue, the
new version of the PCR/ESI-MS technology, named IRIDICA, features improvements in the
methodology and instruments, such as an increase in the volume of blood analyzed (5 mL),
and the enrichment of microbial DNA during the purification process [8].
The overall agreement between IRIDICA and conventional methods was 68.9% when ana-
lyzing by microorganism and 76.6% when analyzing by specimen. Overall, 64 microorganisms
isolated by conventional methods were not detected by IRIDICA (8 from ICU patients and 56
from ER patients). It should be borne in mind that molecular diagnostic assays typically use
smaller volumes of blood (5 mL in this case) than blood culture (up to 30 mL), as the high
amounts of human DNA found in whole blood (mostly in white blood cells) may hamper the
detection of pathogen DNA. This fact could lead to the suboptimal sensitivities commonly
reported for molecular methods in comparison with blood culture [15]. In this sense, Bacconi
et al. [8] demonstrated that IRIDICA performance was not hampered by the presence of up to
4.0×107 white blood cells/mL. In our study no significant difference in white blood cell count
was found between IRIDICA-negative and -positive specimens. However, the two obtained
invalid results corresponded to specimens from ICU patients with a high white blood cell
count (4.5×107 and 7.2×107 cells/mL). It should also be considered that the IRIDICA software
has specific thresholds for reporting different microorganisms and those detections below the
threshold are not reported in order to increase the specificity (3–10 genomes/well for most
pathogenic bacteria, and 10 genomes/well for those microorganisms that can also be found as
skin contaminants). However, this could lead to false negative results in certain cases. In our
study, four microorganisms that were considered the etiological agent of the sepsis episode
were detected but not reported as they were below those levels (data not shown).
The use of blood culture as gold standard when evaluating molecular methods has limita-
tions, given its low positivity rate (only about 10% of all blood cultures are positive) [19,20]. In
this regard, IRIDICA was able to identify an extra 80 microorganisms that did not grow in
blood culture. The detection of 41 (51.2%) of them was supported by the clinical condition of
the patient or other positive cultures (five microorganisms from four ER patients and 36 micro-
organisms from 30 ICU patients), and 39 (40%) were easily identified as contaminants (skin or
environmental). Finally, there were seven microorganisms (8.8%) that are not commonly
found as contaminants and could not be explained by the review of clinical records. These
results reinforce the idea that, like the results of the blood culture, the results obtained with
molecular methods should be interpreted by the clinician in light of clinical signs and symp-
toms. Skin or ambient environmental contaminants can also be found in a small percentage of
blood cultures due to insufficient aseptic practices during extraction (up to 5% of blood cul-
tures in our setting, which is similar to the 5.4% contamination rate found by IRIDICA). When
all the available clinical information was taken into account, IRIDICA showed a positive con-
cordance of 77.2% with respect to clinically diagnosed sepsis. Furthermore, our results are
comparable to those recently published by Bacconi et al.[8], who described a sensitivity ranging
from 83 to 91% in comparison with conventional methods. These results evidence how using a
higher volume of whole blood results in an increased detection rate in comparison with the
previous version of the technology (50% positive agreement) [6].
The IRIDICA platform has been conceived for the rapid diagnosis of infections in critically
ill patients. It should be noticed that this molecular method performed particularly well in the
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subgroup of ICU patients when compared with the clinical infection criterion gold standard;
the sensitivity was 89.0% in the analysis by microorganism vs. 73.1% in the ER (p = 0.005) and
90.5% in the analysis by specimen vs. 73.6% in the ER (p = 0.02). The different performance of
IRIDICA in the ICU and ER settings could be explained, at least in part, by the inherent char-
acteristics of the patients admitted to the ICU. These patients are severely ill and suffering from
underlying pathologies that may increase the risk of developing sepsis. They also have a major
risk of suffering from nosocomial infections due to the use of several intravascular devices,
such as catheters. Besides, patients staying at the ICU setting for a long period of time may suf-
fer from immunological impairment. All these factors may be related to the presence of higher
bacterial loads (a significantly higher number of genomes per well was observed in ICU
patients in comparison with those from the ER). Interestingly, the agreement between IRI-
DICA and the clinical infection criterion was higher than with the blood culture (κ = 0.711 vs.
κ = 0.315), which points to the presence of clinically relevant microorganisms detected only by
the molecular method (73.3% of these patients were under antimicrobial therapy). Finally, IRI-
DICA showed a negative predictive value of 95% in patients admitted to the ICU, indicating
that this technology could be useful for ruling out infection in this setting when the clinical sus-
picion of sepsis is low.
The ability of detecting a broad range of pathogens was demonstrated in this study, as IRI-
DICA was able to detect 43 different species of bacteria and Candida spp. Interestingly, this
technology also detected certain microorganisms that are not commonly recovered from blood
culture, such asMycoplasma hominis andMycobacterium simiae. There were six cases reported
by the software as bacteria or fungus “detected but not identified” (three of each, respectively).
Those detections may indicate the presence of a microorganism that is not usually pathogenic
(in the case of bacteria), or that the software does not have enough information to assign an
identification (for instance, filamentous fungi are not specifically targeted by the assay but can
be amplified by the primers directed to conserved ribosomal genes used for the detection of
Candida spp.). While most of these cases (three bacteria and one fungus) were considered con-
taminants, in two cases the detection could have been due to the presence of Aspergillus fumi-
gatus in blood, as both patients had respiratory cultures positive for this fungus and also had a
positive galactomannan antigen detection. Given that aspergillosis can be a serious complica-
tion in immunocompromised patients, obtaining this information (fungus detected but not
identified) may be useful in order to run additional confirmatory tests and guide treatment.
This study has several limitations. First, only the specimens from patients admitted to the
ICU were consecutively included; while we obtained a dedicated blood specimen from most of
the patients admitted to the ER, only those with a paired positive blood culture were included,
in order to make the study feasible. Thus, the specimen set did not reflect the usual blood cul-
ture positivity rate in the clinical setting (around 10% in our hospital). Nevertheless, the ICU
subanalysis does reflect the positivity rate in this department (7.5–13.7%), and no other studies
have tested as many patients with a positive blood culture using this technology. Secondly, the
specimens were analyzed retrospectively. Thus, we were not able to perform any further testing
when discrepancies were found, especially in those involving resistance markers. Although it
was surprising that the resistance markers vanA and vanB were detected in susceptible Entero-
coccus faecium isolates, this phenomenon has already been described when point mutations or
deletions affect the regulatory genes vanS and vanR [21,22]. Thirdly, the specimens were stored
for varying periods of time at -20°C until tested at IBIS Biosciences. However, long-term stabil-
ity of whole blood samples under these storage conditions had previously been demonstrated
by the manufacturer on spiked samples (unpublished data), and statistical analysis ruled out
any significant association between the storage time and the IRIDICA positivity rate. Finally,
in some cases blood samples were drawn when the patients were already under antibiotic
Early Diagnosis of Bloodstream Infections
PLOS ONE | DOI:10.1371/journal.pone.0140865 October 16, 2015 10 / 13
treatment, which could have led to the detection of clinically relevant microorganisms by the
molecular method in patients with a negative BC.
When implementing molecular methods in the clinical microbiology laboratory, cost-
effectiveness studies are necessary given that molecular methods are more expensive than con-
ventional ones. However, a rapid identification of the pathogen may lead to the optimization of
the administered therapy and, thus, to a prompter recovery of the patient and a shorter stay at
the ICU department. Although prospective cost/benefit studies are needed to assess the real
impact of this technology in the management of septic patients, significant economic savings
have been reported for the molecular SeptiFast assay (Roche, Manheim, Germany) due to the
shortening of the ICU stay and a more rational use of antibiotics [23,24].
In conclusion, the IRIDICA technology offers a rapid and reliable identification of patho-
gens for the diagnosis of sepsis directly from the patient’s blood, with a better performance in
ICU patients. When used in combination with conventional methods it could lead to an
increase in the number of microbiologically confirmed sepsis cases. More importantly, a signif-
icant proportion of septic patients would benefit from an early identification of the pathogen
leading to a prompter appropriate antibiotic treatment, which relates to patient survival rates.
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